Read Larry Connors' blog – Short Term Trading Strategies
- Chen Jonathan W, SVP, Business Development: reported buying $19.62K - Willms Arthur H, Director: reported buying $48.00K Over the last four weeks insiders at Angiotech Pharmaceuticals Inc. (ANPI) have bought more than $126.15K: - Willms Arthur H, Director: bought $48.00K increasing total holdings by 45% - Gross Jeffrey M, SVP, Research and Development: bought $58.52K increasing total holdings by 100% - Chen Jonathan W, SVP, Business Development: bought $19.62K increasing total holdings by 89% For a current, real-time summary of ANPI insider activity, visit http://www.form4oracle.com/company/angiotech-pharmaceuticals-inc-anpi?id=12726 About Form4Oracle Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com. About Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals, Inc. provides technologies and medical products for local diseases and complications associated with medical device implants, surgical interventions, and acute injury in the United States and internationally. Its Pharmaceutical Technologies segment provides technologies that improve the performance of medical devices and the surgical procedures. It also establishes product development and marketing partnerships with various medical device, pharmaceutical, or biomaterials companies. This segment licenses its proprietary paclitaxel technology to the company's partners, as well as sells TAXUS drug-eluting stents. The company's Medical Products segment manufactures a range of single-use specialty medical devices, with products focusing primarily on interventional radiology, biopsy, general surgery, aesthetic surgery, and ophthalmology. It also offers finished medical devices and medical device components for third party medical device manufacturers and marketers. This segment's products include SKATER drainage catheters used to drain fluid from wounds, infectious tissues, or surgical sites; EnSnare retrieval devices used for retrieving devices from vascular structures, organs, or ducts; V+Pad hemostatic pads for managing bleeding wounds; disposable and re-usable soft tissue biopsy needles; BioPince full core biopsy devices; T-Lock bone marrow biopsy devices; HemoStream dialysis catheters; BioSeal lung biopsy systems that prevents air leaks in patients having lung biopsies; and other products, including fixation pins, tunneling stylets and surgical tunnelers, and isotope seed spacers and needles for prostate cancer treatment. Angiotech Pharmaceuticals also offers general surgery products, such as silk and polyester braided and monofilament suture materials; drilled end and channel Needles; ePTFE synthetic vascular grafts; and surgical blades for cataract surgery. The company was founded in 1989 and is headquartered in Vancouver, Canada. -------------------------------------------- The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard. Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein. FOR FURTHER INFORMATION: please contact Kimberly Sutton, on behalf of Form4Oracle, kimberly@form4oracle.com or +1 312 315 5077. CONTACT: Kimberly Sutton, Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. For full details on Angiotech Pharmaceutical (ANPI) click here. Angiotech Pharmaceutical (ANPI) has Short Term PowerRatings of 4. Details on Angiotech Pharmaceutical (ANPI) Short Term PowerRatings is available at This Link.
Email Print Archives Feedback Email Article Link
Close X
Most Popular News
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
Premium Subscription Services
RELATED SITES
Please call 1-213-955-5858 ext. 1
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. The Connors Group, Inc. © Copyright 2009 The Connors Group, Inc. All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy. © 2009 The Connors Group, Inc.
|
